Segment Information (Tables)

3 Months Ended

Mar. 31, 2026

Reconciliation of revenue from segments to consolidated

The following table includes additional information about reported segment revenue, significant segment expense and segment measure of profitability:


	For the Three Months Ended March 31,
(In millions)	2026		2025
Total revenue	$	2,477.8	$	2,431.0
Less cost and expense:
Cost of sales, excluding amortization and impairment of acquired intangible assets:
Product cost of sales	478.7		462.2
Royalty cost of sales	182.3		167.1
Research and development:
Research and discovery	40.5		44.3
Early stage programs	69.0		72.4
Late stage programs	102.5		49.4
Marketed products	154.2		89.5
Other research and development costs(1)	172.8		178.5
Acquired in-process research and development, upfront and milestone expense	34.0		200.7
Selling, general and administrative	607.3		572.5
Other segment expense(2)	317.0		353.9
Net Income attributable to Biogen Inc.	$	319.5	$	240.5

(1) Other research and development costs primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses and are not allocated to a specific program or stage.

(2) Other segment expense includes: amortization and impairment of acquired intangible assets; collaboration profit sharing/(loss reimbursement); (gain) loss on fair value remeasurement of contingent consideration; restructuring charges; other (income) expense, net; and income tax (benefit) expense